Bitcoin dropped in 93% of four-week periods when global stocks fell over 5%, with an average 13% decline compared to gold's 0.4% gain, highlighting Bitcoin's weak performance during sharp equity downturns. Over a longer term, Bitcoin's monthly returns showed a low correlation (0.18) with the S&P 500, indicating some independence from stock markets. Bitcoin and Ether also exhibit much higher volatility than stocks, with annualized volatility of 60% and 79% respectively, compared to 19% for the S&P 500. These findings suggest Bitcoin has not consistently acted as a portfolio hedge during equity market weakness, unlike gold.
Bitcoin's recent performance during global stock declines is the subject, with Pluang market data as context for readers. As of Oct 26, 2026 17:21 WIB, among 50 major cryptocurrencies on Pluang, 26 rose and 22 fell. Notable price changes include CAKE at Rp38.461 (+3.32%, 94% Sell), ALGO at Rp1.888 (+2.55%, 98% Sell), and BCH at Rp5.026.753 (+2.49%, 81% Sell).
Corxel Pharmaceuticals US and Amanat Acquisition Corp have agreed to merge, creating a publicly traded biopharmaceutical company focused on oral obesity treatments. The deal will raise approximately $377 million, including $300 million from private i...
Eikon Therapeutics presented updated data on EIK1001, a TLR7/8 dual-agonist, combined with pembrolizumab and chemotherapy for stage 4 non-small cell lung cancer (NSCLC) at the 2026 ESMO Congress. The treatment showed a 72% objective response rate and...
Microsoft, Alphabet, and Amazon together represent about 15% of the S&P 500 index. All three tech giants are scheduled to report their quarterly earnings within a two-day span. These earnings reports are highly anticipated as they provide insight int...
Conow, in partnership with Tuya Smart, has introduced the Atlas 6000 AC in Germany, a 6 kWh AC-coupled plug-and-play home battery designed to upgrade existing rooftop solar systems. This battery features AI-driven energy management that optimizes hou...
BioNTech and DualityBio announced that their Phase-3 clinical trial DYNASTY-Breast02 met its primary endpoint, demonstrating a statistically significant but moderate improvement in progression-free survival for Trastuzumab Pamirtecan compared to chem...
